Brief: Esperion Secures Additional Commercial And Medicare Formulary Coverage For Nexletol(Bempedoic Acid) And Nexlizet(Bempedoic Acid And Ezetimibe)
03/09/2024 13:46
Sept 3 (Reuters) - Esperion Therapeutics Inc ESPR.O :
* ESPERION SECURES ADDITIONAL COMMERCIAL AND MEDICARE
FORMULARY
COVERAGE FOR NEXLETOL® (BEMPEDOIC ACID) AND NEXLIZET® (BEMPEDOIC
ACID AND EZETIMIBE)
Source text for Eikon: ID:nGNX8XDYkK
Further company coverage: ESPR.O
((Reuters.Brief@thomsonreuters.com;))
Recent news on Esperion Therapeutics
See all newsNASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:58 AM
NASDAQ TRADE HALT CONTINUES TRADING HALTED; FOR INFORMATION REQUESTED BY NASDAQ AT 03:28 AM
NASDAQ TRADE HALT CONTINUES TRADING HALTED; FOR INFORMATION REQUESTED BY NASDAQ AT 03:28 AM
NASDAQ TRADE HALT TRADING HALTED; FOR INFORMATION REQUESTED BY NASDAQ AT 07:50 PM
U.S. RESEARCH ROUNDUP- Applied Materials, Axsome Therapeutics, Onsemi